Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

Not Recruiting

Trial ID: NCT01326364

Purpose

The purpose of this study is first, to determine whether baseline perfusion characteristics of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to determine whether baseline perfusion characteristics in those patients with resectable pancreatic cancer correlate with immunohistologic markers of angiogenesis such as microvessel density and vascular endothelial growth factor (VEGF) expression.

Official Title

Prognostic Value of Baseline CT Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

Stanford Investigator(s)

Brendan C. Visser, MD
Brendan C. Visser, MD

Professor of Surgery (General Surgery)

George A. Poultsides, MD, MS
George A. Poultsides, MD, MS

Professor of Surgery (General Surgery)

George A. Fisher Jr.
George A. Fisher Jr.

Colleen Haas Chair in the School of Medicine

Dominik Fleischmann
Dominik Fleischmann

Professor of Radiology (Cardiovascular Imaging)

Eligibility

Inclusion Criteria:

1. suspected and/or biopsy-proven pancreatic adenocarcinoma, and
2. referral to Radiology for pre-treatment baseline pancreatic protocol CT.

Exclusion criteria:

1) are absolute contraindications to intravenous iodinated contrast or CT scan.

Intervention(s):

procedure: Stereotactic body radiotherapy

drug: Iodixanol

drug: Iohexol

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
ccto-office@stanford.edu
650-498-7061

New Trial Alerts